Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D8SV9R
|
|||
| Drug Name |
DNX-2401
|
|||
| Synonyms |
Tasadenoturev
Click to Show/Hide
|
|||
| Drug Type |
Oncolytic virus therapy
|
|||
| Indication | Brain cancer [ICD-11: 2A00] | Phase 2 | [1] | |
| Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 2 | [2] | ||
| Company |
DNAtrix
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT02798406) Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE). U.S. National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT02798406) Combination Adenovirus + Pembrolizumab to Trigger Immune Virus Effects (CAPTIVE). U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.